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Circulating Plasma microRNAs can 
differentiate Human Sepsis and 
Systemic Inflammatory Response 
Syndrome (SIRS)
Stefano Caserta1, Florian Kern1, Jonathan Cohen1, Stephen Drage2, Sarah F. Newbury1 & 
Martin J. Llewelyn1,2
Systemic inflammation in humans may be triggered by infection, termed sepsis, or non-infective 
processes, termed non-infective systemic inflammatory response syndrome (SIRS). MicroRNAs 
regulate cellular processes including inflammation and may be detected in blood. We aimed to establish 
definitive proof-of-principle that circulating microRNAs are differentially affected during sepsis and 
non-infective SIRS. Critically ill patients with severe (n = 21) or non-severe (n = 8) intra-abdominal 
sepsis; severe (n = 23) or non-severe (n = 21) non-infective SIRS; or no SIRS (n = 16) were studied. 
Next-generation sequencing and qRT-PCR were used to measure plasma microRNAs. Detectable blood 
miRNAs (n = 116) were generally up-regulated in SIRS compared to no-SIRS patients. Levels of these 
‘circulating inflammation-related microRNAs’ (CIR-miRNAs) were 2.64 (IQR: 2.10–3.29) and 1.52 (IQR: 
1.15–1.92) fold higher for non-infective SIRS and sepsis respectively (p < 0.0001), hence CIR-miRNAs 
appeared less abundant in sepsis than in SIRS. Six CIR-miRNAs (miR-30d-5p, miR-30a-5p, miR-192-5p, 
miR-26a-5p, miR-23a-5p, miR-191-5p) provided good-to-excellent discrimination of severe sepsis 
from severe SIRS (0.742–0.917 AUC of ROC curves). CIR-miRNA levels inversely correlated with pro-
inflammatory cytokines (IL-1, IL-6 and others). Thus, among critically ill patients, sepsis and  
non-infective SIRS are associated with substantial, differential changes in CIR-miRNAs. CIR-miRNAs 
may be regulators of inflammation and warrant thorough evaluation as diagnostic and therapeutic 
targets.
Sepsis is defined as a systemic inflammatory response syndrome (SIRS) driven by infection1. Severe sepsis (sepsis 
accompanied by acute organ dysfunction) is a leading cause of death worldwide and the most common cause 
of death among patients on Intensive Care Units (ICUs)2. Critically ill patients may also develop SIRS driven by 
non-infective processes such as tissue ischemia. Sepsis and non-infective SIRS are hard to differentiate clinically 
but have very different therapeutic implications.
Understanding the immunopathology of sepsis and non-infective SIRS is vital for the development of novel 
diagnostics and treatments and for the appropriate use of antibiotics and novel immunotherapies. Much is known 
about the inflammatory responses which underlie sepsis and biomarkers of inflammation have been identified3. 
However there is growing recognition of the importance of anti-inflammatory, regulatory processes which 
accompany SIRS and sepsis4. These are physiological in that they terminate inflammation during recovery, and 
may be pathological causing sepsis-related immunosuppression. Ultimately, understanding how SIRS and sepsis 
are regulated may be key to developing novel biomarkers and interventions5.
MicroRNAs (miRNAs) are small (~22 nt) regulatory RNAs that function as post-transcriptional gene 
regulators6,7. Out of the 2588 described human miRNAs (miRBase.org), approximately 200 miRNAs have 
been reported circulating in the human blood in health and disease8–10. The impact of disease on circulating 
miRNAs has been assessed principally in the context of cancer11–13. A handful of studies have measured miRNAs 
present in the blood of sepsis patients, and reported conflicting findings14–21. Other studies have assessed spe-
cific candidate miRNAs based on leukocyte inflammatory responses in experimental models22–26. Advances in 
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array and sequencing technologies now allow genome-wide screening for miRNAs, directly in human serum and 
plasma27,28, but studies which have taken this approach have been hampered by lack of robust normalization to 
properly quantify miRNA levels, small sample sizes and heterogeneous patient populations14,17.
In this study, we set out to establish definitive proof-of-principle that circulating microRNAs are differ-
entially affected during systemic inflammation in critically ill patients depending on etiology. We studied a 
cohort of patients robustly characterized at the time of admission to critical care29 and selected tightly defined 
groups of patients with sepsis, non-infective SIRS, and critical illness without SIRS (no-SIRS patients). We used 
next-generation sequencing (NGS30) to identify normalizer miRNAs (present at consistent levels between patient 
groups) and to establish a long-list of candidate miRNAs differentially present in the blood of patients with sep-
sis, non-infective SIRS and without SIRS. We then used miRNA qRT-PCR to validate the most differentiating 
miRNAs and explore their performance in distinguishing sepsis from non-infective SIRS used singly and in 
combination.
We find that there is a general increase in the levels circulating miRNAs in the blood of patients with sepsis 
or non-infective SIRS compared with controls, and that this is more marked for non-infective SIRS than sepsis 
patients. We term these circulating inflammation-related miRNAs (CIR-miRNAs). Furthermore we find that 
the levels of CIR-miRNAs are differentially affected in sepsis and non-infective SIRS. Of note, among sepsis and 
SIRS patients, the blood levels of CIR-miRNAs inversely correlate with the plasma levels of key pro-inflammatory 
mediators such as interleukin-(IL)-1, IL-6, IL-8 and C-reactive protein (CRP), previously identified in systemic 
inflammation and sepsis3,29. CIR-miRNAs may be anti-inflammatory regulators of inflammation in patients with 
sepsis or non-infective SIRS and further investigation of their function and potential as disease markers and 
therapeutic targets is warranted.
Materials and Methods
Study Population. Patients comprised unselected adult admissions to a mixed medical/surgical intensive/
high-dependency care unit (ICU/HDU) at an English acute hospital (Brighton and Sussex University Hospitals 
NHS Trust). For each patient, we gathered data describing demographics, reason for admission to ICU/HDU 
(i.e., medical/surgical patient), severity of illness (Sequential Organ Failure Assessment (SOFA) score in the first 
24 hours), comorbidities, focus of infection, and routine clinical blood test results. Patients were categorized as 
having sepsis, non-infective SIRS or no-SIRS using standard criteria29. To minimize heterogeneity within groups, 
we included only patients with abdominal sepsis (defined as surgically or radiologically identified focus of infec-
tion within the abdomen) and defined distinct levels of severity: severe (SOFA ≥ 6) and non-severe (SOFA ≤ 3) 
sepsis/SIRS; patients with intermediate SOFA scores of 4–5 were excluded, defining 5 experimental groups 
(Table 1). Study blood samples were collected within a median time of 0.78 (IQR: 0.30–2.5; n = 89) hours of ICU 
admission with a maximum collection time of 5.8 hours. There was no statistical difference (p = 0.740, ANOVA) 
in time of sample collection between the groups (Table 1).
Ethics Statement. Written informed consent or consultee approval to enroll was secured for all study par-
ticipants. Under the UK Law (Mental Capacity Act) a consultee is someone (usually a next of kin, friend or family 
member) who gives approval for a patient who lacks capacity to be enrolled to a study, thus allowing such patients 
to participate in studies addressing the illness which affects them. This study was approved by the North Wales 
Research Ethics Committee (Central and East, reference 10/WNo03/19) and carried out in accordance with the 
approved guidelines. All data were anonymized.
Preparation of NGS samples from plasma. Red blood cell (RBC) lysis can bias microRNA content 
in plasma31,32. The concentration of free hemoglobin ([Hb]) was measured in patient plasma by the Harboe 
spectrophotometric method33,34 and hemolytic35 samples with [Hb] > 0.6 g/L36 were excluded. Plasma pools 
were formed by combining equal volumes of patients’ plasma (Table 1). Total RNA was then extracted using the 
miRVanaTM PARISTM kit (Life Technologies)13. On average, we recovered 679 ± 165 pg RNA/μ l plasma 
(mean ± SD); of this 849 ± 206 ng (mean ± SD) RNA (stored at − 80 °C) were used for NGS technical duplicates. 
NGS cDNA libraries were prepared and validated at ARK Genomics (University of Edinburgh, UK) using spe-
cific barcodes for each cDNA library (Illumina TruSeq Small RNA sample) following manufacturer instructions. 





Time to sample 
(hours) CRP (ng/ml) PCT (ng/ml) F:M ratio (♀%)
[Hb] mg/L 
plasma
Severe SIRS 23 58.5 ± 17.0 7.56 ± 2.31 6:17 0.73  (IQR: 0.22–2.3) 19.8 ± 32.7 1.73 ± 3.85 12:11 (52.2%) 155 ± 110
Severe Sepsis 21 67.7 ± 12.9 8.19 ± 2.68 21:0 0.88  (IQR: 0.33–2.5) 156 ± 76.9 21.9 ± 28.7 13:8 (61.9%) 215 ± 145
Non-severe SIRS 21 61.0 ± 14.0 1.29 ± 0.96 18:3 0.67  (IQR: 0.41–2.8) 20.6 ± 34.3 0.29 ± 0.34 12:9 (57.1%) 216 ± 159
Non-severe Sepsis 8 58.1 ± 23.3 1.13 ± 0.99 8:0 1.6  (IQR: 0.40–4.2) 159 ± 69.5 5.77 ± 9.66 3:5 (37.5%) 115 ± 96.3
NO SIRS 16 64.9 ± 14.6 4.19 ± 3.41 15:1 0.70  (IQR: 0.14–2.4) 19.2 ± 20.3 0.77 ± 1.00 11:5 (68.7%) 160 ± 133
Table 1.  Demographics, severity of illness and key inflammatory biomarkers of the patients used in the 
study.
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The libraries were finally eluted from gels, validated (for purity and correct insert size: 146 bp corresponding to 
~22 nucleotides) on the High Sensitivity D1K ScreenTape (Agilent Technologies) and quantified by quantitative 
polymerase chain reaction (qPCR) prior to sequencing (Illumina HiSeqTM 2500). In each lane, ~108 NGS reads 
were acquired and, after filtering and sorting by library barcodes, sequences in any sample were mapped to miR-
Base (release 20) database. The resulting mapped reads (called counts) were arbitrarily normalized as miRNA 
counts/105. See Supplementary Material and Methods for further detail. Raw sequencing data is available at the 
repository ArrayExpress (Accession number: E-MTAB-4637).
Identification of miRNA normalizers in plasma. To identify miRNAs stably expressed in sep-
sis and SIRS relative to no-SIRS patients, for each average NGS miRNA count (technical duplicates, 5 groups 
Figure 1. Patients plasma tested for miRNAs in Illumina NGS. Plasma total RNA was extracted from 10 
pools (representative of 89 ICU patients, as in Table 1) using the miRVana PARIS technology and then human 
miRNAs were sequenced using the Illumina next generation sequencing (NGS) platform. (A) Representative 
plots show the number of blood miRNAs (x-axis, sorted based on their abundance in the first duplicate of 
SIRS) and relative NGS counts (y-axis), in SIRS, sepsis and no-SIRS patients. Many miRNA were expressed 
below 1/105 NGS counts (orange shadowed areas) consistently across all pools and were excluded from further 
analysis. (B) Prolife of miRNA distribution after miRNAs with < 1/105 counts (orange areas) in all pools were 
excluded. (C) miRNA counts in 2 identical replicates are shown in scatter plots for SIRS, sepsis and no-SIRS 
patients. Reproducible results were obtained for miRNAs with NGS counts > 10/105 (red lines) and miRNA in 
the grey area were excluded. (D) The average miRNA counts (shortlisted in A–C, n = 116) from severe SIRS 
and Sepsis groups was expressed as a ratio against no-SIRS controls (left and middle panels) or in between each 
others (right panel), resulting in fold differences (fd) for each blood miRNA (histograms). Green and red areas, 
respectively, represent miRNA decrease and increase, separated by fd = 1 (left dotted line) and fd = + 2 (right 
dotted line). Compared to no-SIRS, many CIR-miRNAs had fd > + 2 in SIRS (left), but not in sepsis (fd < + 2, 
middle). When Sepsis/SIRS are compared CIR-miRNAs are mostly downregulated (right).
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representative of 89 individuals) we calculated: (i) percentage residual counts relative to average counts across 
groups and (ii) fold-differences (fd) between sepsis and SIRS (severe and non-severe). Normalizer candidates 
had: percentage residual counts within ± 20% when comparing any inflammatory disease group to no-SIRS and 
fd = 1.00 ± 0.20 (i.e. not more than 20% differential NGS counts in severe/non-severe sepsis vs SIRS).
microRNA real-time qPCR array and cytokine analysis. Total plasma RNA was extracted from indi-
vidual patients using the miRCURY™ RNA isolation-biofluids kit (Exiqon, Denmark). RNA was reverse tran-
scribed (RT) and cDNA analyzed using the miRCURY LNA™ Universal RT microRNA PCR, Polyadenylation 
and cDNA synthesis method (Exiqon, see Supplementary Material and Methods for details). Each microRNA 
was assayed by qPCR (microRNA Ready-to-Use PCR, Pick-&-Mix using ExiLENT SYBR® Green master mix) 
in 2 independent technical repeats including negative controls (no-template from the RT reaction) using a 
LightCycler® 480 Real-Time PCR System (Roche). In each experimental group, ≥ 8 biological replicates were 
included. Assays returning 3 crossing point (Cp) values less than the negative control and Cp < 37 were accepted. 
The stability values of candidate normalizers were assessed using the ‘NormFinder’ software37. Any qPCR data 
was normalized to the average Cp of internal normalizers detected in all samples (delta Cp, dCp = normalizer 
Cp–assay Cp). Cytokines were measured on Luminex LX200 as before29 (see Supplementary Material and 
Methods).
Statistical analyses. Datasets were analyzed using the GraphPad Prism 6 and/or IBM SPSS Statistics 22 
software. The D’Agostino and Pearson omnibus and/or Shapiro-Wilk tests were used to test normal data distri-
bution. If not normally distributed, medians with interquartile ranges (IQR, rather than means and standard 
deviation, SD) are shown and Mann-Whitney U Test (rather than t-tests) were used to calculate p-values in 
2-group comparisons. Significances across more than 2 groups were assessed by ANOVA (Kruskal-Wallis test). 
For the qPCR miRNA array dataset, a Benjamini-Hochberg p-value correction38 was used to control for the num-
ber of false positives. The CIR-miRNA score (generated by binary logistic regression to predict SIRS vs sepsis) 
linearly combined the top performing 6 miRNA measurements in severe sepsis/SIRS patients. Multivariable anal-
ysis to correct for the effects of confounding variables was conducted using hierarchical multiple regression and 
hierarchical binary logistic regression (refer to Supplementary Materials and Methods for details). Correlations 
between CIR-miRNA scores and plasma levels of inflammatory mediators were evaluated using the Spearman 
rho and significances of the correlations. miRNA and cytokine analyses were conducted blind to the clinical data.
Results
Patients. Plasma samples used in the study came from 91 critically ill patients. Two samples with free hemo-
globin (Hb) > 0.6 g/L were excluded as hemolytic from further analysis (Supplementary Fig. 1A), leaving 89 sam-
ples divided into five groups (Supplementary Fig. 1B): severe sepsis (n = 21); non-severe sepsis (n = 8); severe 
non-infective SIRS (n = 23); non-severe non-infective SIRS (n = 21); and patients without SIRS (no-SIRS con-
trols, n = 16). Data describing demographics, clinical characteristics, sampling, severity of illness and key inflam-
matory biomarkers for study participants are shown in Table 1.
The median age of the patients was 66 years (IQR 54–75 years), 38 (43%) were male. Groups were well 
matched for age and gender (p = 0.229 and p = 0.638 respectively). By definition all 29 sepsis patients had an 
Figure 2. Shortlisting of internal normalizers in NGS and miRNA Q-PCR arrays. Plasma total RNA 
extracted and analyzed in NGS as described in Fig. 1, in 10 duplicate plasma pools (5 groups representative 
of 89 individuals) (A) or in 89 individuals samples using the miRCURY LNA Universal RT microRNA PCR 
technology (B). (A) Among the finally shortlisted miRNAs (miR-320a, miR-92-3p and miR-486-5p), the 
fold-differences (fd) of average NGS counts seen in severe and non-severe sepsis and SIRS groups (8 pools 
representative of 73 individuals) relative to no-SIRS controls (2 duplicate pools, n = 16) are shown. (B) In 
miRNA qPCR arrays, normalizer miRNAs were tested for 89 individual patients in 5 groups: severe sepsis 
(n = 21); non-severe sepsis (n = 8); severe SIRS (n = 23); non-severe SIRS (n = 21); and patients without SIRS 
(no-SIRS controls, n = 16), in two independent technical repeat experiments. Because miR-92b-3p was below 
the level of detection in 22/89 patients, it was excluded from further analysis. The mean Cp of the miR-320a 
and miR-486-5p is shown in each group and was selected as an internal normalizer for the miRNA qPCR array 
dataset.
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Figure 3. Shortlisted CIR-miRNAs measured with Exiqon miRNA qPCR arrays. In miRNA qPCR arrays, 
within each patient’s specimen, Cp of a single miRNA is compared to the mean Cp of 2 normalizers (as from 
Fig. 2) to give delta-Cp (dCp). dCp of all patients are analyzed, comparing severe Sepsis (D, n = 21) and SIRS 
(A, n = 23). (A) Volcano plot shows fold changes (log2, D/A) relative to p values (−log10) in each miRNA 
assay. In the upper left quadrant of the plot, around 20 miRNAs are significantly (red and yellow dots above 
the horizontal black line, which indicates a level of significance p ≤ 0.05) downregulated in D/A (fd < − 1.5, 
left vertical line), see Table 2. Orange and red dots represent significant differences by t-test (p < 0.05) with red 
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abdominal focus and all had surgical or radiological interventions. Non-sepsis patients were more heterogeneous 
with 39/60 (65%) being surgical (cancer surgery 17, abdominal surgery 16, cardiac surgery 4, and trauma 2), 
whilst the remainder were mixed medical patients. Patients with severe sepsis and severe non-infective SIRS had 
similar SOFA scores (Mean ± SD: 8.19 ± 2.68 and 7.56 ± 2.31 respectively, p = 1.00) which were markedly higher 
than in patients with non-severe disease 1.13 ± 0.99 and 1.29 ± 0.96 (p < 0.0001 both for sepsis and non-infective 
SIRS). Patients with severe sepsis had markedly higher levels of C-reactive protein (CRP: 161.8 ng/ml; IQR 
109.5–215.7 ng/ml) and procalcitonin (PCT: 8.8 ng/ml; IQR 2.15–39.2 ng/ml) than patients with severe SIRS 
(CRP: 5.50 ng/ml; IQR 1.90–18.2 ng/ml, p < 0.0001 and PCT: 0.20 ng/ml; IQR 0.10–1.10 ng/ml, p = 0.0002). PCT 
levels also tended to be lower among patients with mild rather than severe sepsis (1.40 ng/ml; IQR 0.32–8.82 ng/
ml) but this was not statistically significant (p = 1).
Identification of plasma inflammation-related miRNAs by NGS. In order to identify which of the 
currently known 2588 human miRNAs are found in the blood of critically ill patients with and without SIRS, we 
used NGS to sequence and differentially quantitate miRNAs in plasma pools comprising all patients in five groups 
(Table 1). Plasma pools were preferred to individual samples because they decrease the impact of individual 
outliers on the analysis. To control for the bias of miRNAs from RBC in differential analysis, we compiled pools 
so that average levels of hemolysis were comparable (Supplementary Fig. 1B and Table 1). Total RNA was then 
extracted from equal volumes of plasma and technical duplicates of cDNA libraries for Illumina NGS created. 
Results from 10 pools representative of 89 individuals are shown in Fig. 1. On average, NGS reads/library were 
7.94 ± (SD) 1.36 × 106 and miRBase-mapped reads (counts) were 43.5 ± (SD) 7.2%. Just below half of human 
microRNAs listed in miRBase.org (1097) returned counts in NGS (Fig. 1A) and were similarly distributed in 
each group. miRNAs present at low levels (< 1 read per 105 NGS counts across all five groups; Fig. 1A, orange 
area) showed high variability between the technical replicates and were excluded from further analysis. 244 
miRNAs were expressed above > 1/105 counts (Fig. 1B) in at least one group and among these concordance 
between replicates was poor if average counts were < 15/105 (Fig. 1C, grey area) consistently across groups, leav-
ing 116 miRNAs for subsequent analysis (Fig. 1D and Supplementary Table 1).
For each miRNA, fold differences (fd) were calculated comparing average counts in severe SIRS and sepsis 
with no-SIRS patients (Fig. 1D). Highly significant differences were seen when comparing plasma from patients 
with non-infective SIRS and patients with sepsis relative to no-SIRS controls, with the median fd for miRNAs 
being 2.64 (IQR: 2.10–3.29) and 1.52 (IQR: 1.15–1.92) respectively (p < 0.0001 and n = 116 for each compar-
ison). We henceforth term the blood miRNAs that are affected in sepsis and non-infective SIRS, circulating 
inflammation-related miRNAs (CIR-miRNAs). In addition, when directly comparing sepsis and non-infective 
SIRS, CIR-miRNA levels were markedly lower in sepsis patients (median fd = 0.53; IQR: 0.45–0.74) (Fig. 1D, 
right panel).
Identification of normalizer miRNAs. To allow for robust comparison of miRNA levels in blood between 
individual samples we used NGS data to identify normalizer miRNAs present at consistent levels across the four 
inflammatory disease groups (Fig. 2A, n = 73) relative to the no-SIRS (n = 16) controls. This identified three 
candidate normalizers: miR-320a, miR-92b-3p and miR-486-5p that were expressed at stable levels across all 
inflammatory patient groups with levels varying by < 20% (Fig. 2A).
We validated these candidate NGS normalizers using qPCR miRNA arrays on individual patient samples 
(n = 89, Fig. 2B). While miR-92b-3p was below the level of detection in 22/89 patients, the optimal normalizer 
(by NormFinder stability value37) was the average Cp of miR-320a and miR-486-5p. This performed better than 
any other single miRNA detected and was consistent across all 89 patients (Fig. 2B).
Identification of a set of miRNAs which discriminate severe sepsis from SIRS. We applied 
qRT-PCR to validate the NGS results and determine if the general decrease in CIR-miRNAs observed in sepsis 
compared with non-infective SIRS could be used to distinguish these states at an individual patient level.
To maximize the possibility to detect reliable candidates we selected CIR-miRNAs for high level of detec-
tion in blood (by excluding CIR-miRNAs with consistently less than 35/105 NGS counts in any group) and with 
fd ≤ 0.66 or fd ≥ 1.5 (when comparing sepsis to SIRS), leaving a panel of 47 CIR-miRNAs (including normalizers) 
to be validated in 89 patient samples. For each patient sample, Cp of single miRNAs were compared to the mean 
Cp of internal normalizers, to give delta-Cp (dCp). In parallel, we scored hemolysis in qPCR miRNA arrays as 
miR-23a/miR-451a ratio and excluded one sample that scored > 739 from further analysis (Supplementary Fig. 2).
dCp were analyzed of patients with severe Sepsis (n = 21, group D in Fig. 3) and non-infective SIRS (n = 23, 
group A in Fig. 3). Confirming our NGS analysis (Fig. 3 and Table 2), the majority (~94%) of CIR-miRNAs had 
negative fold changes in qPCR analysis in the sepsis group compared with non-infective SIRS (Volcano plot 
in Fig. 3A). Table 2 lists 20 CIR-miRNAs that were statistically significantly decreased (t-test, p < 0.05) includ-
ing the top 6 differentially expressed that passed the Benjamini-Hochberg correction38 (respectively, the yel-
low and red dots above the horizontal black line, p ≤ 0.05, and with fd ≤ − 1.5, left vertical line in Fig. 3A). No 
CIR-miRNAs were statistically significantly increased in severe sepsis compared to severe non-infective SIRS 
dots representing miRNA that also passed the Benjamini-Hochberg correction. No CIR-miRNA significantly 
increased in D/A. (B) Heatmap shows the top 12 significant miRNA clustering with opposite patterns in D/A. 
(C) Principal component analysis (PCA) transforms the top 5 significant miRNAs to maximize the visualization 
of differences across the severe sepsis and SIRS groups. The PCA plot shows that within the dataset it is possible 
to discriminate patients with SIRS (blue dots, mostly in the lower right quadrant of the PCA plot) away from 
patients with sepsis (Fig. 3C, green dots falling in other quadrants).
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(Fig. 3A). Furthermore, the top-12 significantly different CIR-miRNAs showed inverse patterns in sepsis and 
SIRS (heatmap in Fig. 3B).
To determine whether severe sepsis and non-infective SIRS are associated with distinct patterns of change 
in CIR-miRNAs we conducted a principal component analysis. A combination of top 5 significantly different 
CIR-miRNAs (miR-30d-5p, miR-30a-5p, miR-192-5p, miR-26a-5p and miR-23a-5p) was sufficient to achieve 
discrimination of severe sepsis from non-infective SIRS patients (Fig. 3C).
Relative to normalizers, dCp values in severe SIRS were significantly higher than in sepsis (Fig. 4A), indicating 
that CIR-miRNAs are more abundant in SIRS than in sepsis patients. When the data were plotted as receiver oper-
ator curves (ROC) each of the top 6 significantly different CIR-miRNAs (additionally including miRNA-191-5p) 
provided good to excellent discrimination with areas under the curve (AUC) between 0.742 to 0.861 (Fig. 4A). 
Hierarchical logistic regression (Supplementary Fig. 4A) confirmed that the predictive value of these 6 miRNAs 
is retained after controlling for SOFA score; age; sex; patient survival outcome and time of sample collection.
We further created a model combining levels of these 6 CIR-miRNAs into a score that maximized the dis-
tinction between non-infective SIRS and sepsis (Fig. 4B). In the model interpolation of the cohort, non-infective 
SIRS and sepsis patients tended to score respectively > 0 and < 0; hence the higher the model score the more 
likely patients are to have non-infective SIRS rather than sepsis, as described by a concomitant increase of mul-
tiple CIR-miRNAs (CIR-miRNA score). The ROC curves with AUC 0.917 (Fig. 4B, right) and AUC 0.89 (after 
multivariable correction analysis, as shown in Supplementary Fig. 4) for the model interpolation data show that 
the top-6 significant CIR-miRNAs combined together outperformed any single miRNA. Moreover, CIR-miRNAs 
either combined or used singularly mimicked and even outperformed the traditional sepsis biomarker, PCT 
(Supplementary Fig. 3).
Levels of CIR-miRNAs are inversely correlated with that of inflammatory cytokines. We 
obtained CIR-miRNA scores as a mathematical function of the plasma levels of 6 CIR-miRNAs found to be con-
sistently reduced in sepsis (and preferentially leading to score < 0). The CIR-miRNA scores were then correlated to 
plasma levels of pro-inflammatory mediators, and SOFA severity scores, across sepsis and SIRS patients (Fig. 5). 
CIR-miRNA scores did not correlate with SOFA scores (Fig. 5A). However, CIR-miRNA scores negatively corre-
lated with levels of pro-inflammatory mediators, suggesting that a marked increase of multiple CIR-miRNAs is 
significantly associated with low levels of pro-inflammatory markers (CRP and PSP, Fig. 5B) and cytokines (IL-1, 
IL-8 and IL-6, Fig. 5C). Thus, in severe inflammatory disease, the levels of CIR-miRNAs change in the opposite 
direction to levels of pro-inflammatory mediators.
Discussion
We have undertaken a robust exploratory evaluation of circulating miRNAs among critically ill patients 
with sepsis and non-infective SIRS in comparison with internal control patients. We identified circulating 
inflammation-related miRNAs (CIR-miRNAs) that are broadly increased in both sepsis and non-infective SIRS 
patients when compared with no-SIRS controls. Among patients with severe sepsis, CIR-miRNA levels were lower 
than in patients with comparably severe non-infective SIRS. Furthermore, we have identified six CIR-miRNAs 














hsa-miR-30d-5p 1.08 0.76 − 4.94 − 3.51 − 2.70 0.000014 0.00061
hsa-miR-30a-5p 1.09 1.74 − 6.94 − 5.13 − 3.50 0.00030 0.0064
hsa-miR-192-5p 1.45 1.49 − 4.56 − 2.90 − 3.16 0.00072 0.010
hsa-miR-26a-5p 1.49 1.08 − 2.85 − 1.51 − 2.53 0.0018 0.017
hsa-miR-23a-3p 1.29 0.77 0.90 2.00 − 2.14 0.0020 0.017
hsa-miR-191-5p 0.96 0.98 − 1.55 − 0.60 − 1.94 0.0026 0.018
hsa-let-7f-5p 1.52 0.96 − 4.23 − 3.16 − 2.10 0.0099 0.061
hsa-miR-122-5p 2.49 3.22 − 2.85 − 0.59 − 4.80 0.014 0.073
hsa-miR-101-3p 1.05 0.81 − 2.92 − 2.20 − 1.64 0.018 0.084
hsa-miR-30c-5p 1.57 1.09 − 4.07 − 3.09 − 1.97 0.023 0.085
hsa-miR-151a-3p 1.28 0.82 − 4.16 − 3.36 − 1.73 0.024 0.085
hsa-miR-378a-3p 1.44 1.25 − 4.16 − 3.17 − 1.99 0.025 0.085
hsa-miR-223-3p 1.50 1.26 3.30 4.27 − 1.96 0.027 0.085
hsa-miR-27b-3p 1.76 0.92 − 2.93 − 1.95 − 1.98 0.030 0.085
hsa-let-7a-5p 1.47 0.81 − 0.69 0.14 − 1.78 0.030 0.085
hsa-miR-146a-5p 1.22 0.84 − 1.71 − 1.00 − 1.64 0.033 0.089
hsa-miR-107 0.97 0.87 − 2.45 − 1.86 − 1.50 0.043 0.10
hsa-let-7b-5p 0.67 0.63 − 0.96 − 0.54 − 1.33 0.044 0.10
hsa-miR-30e-3p 1.05 1.12 − 6.65 − 5.96 − 1.62 0.046 0.10
hsa-miR-143-3p 1.73 1.30 − 4.54 − 3.57 − 1.97 0.048 0.10
Table 2.  Significant differentially-expressed miRNAs in severe Sepsis (D) compared to SIRS (A).
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Figure 4. CIR-miRNAs are good-to-excellent biomarkers of sepsis. In miRNA qPCR arrays, data was analyzed 
as in Fig. 3 and the top-6 differentially expressed miRNA in sepsis compared to SIRS (after the Benjamini-
Hochberg correction) are shown. (A) Left dot plots show dCp values in severe SIRS vs sepsis in individual 
samples (n = 21 and n = 23 for sepsis and SIRS respectively, except n = 20 in sepsis for miRNA-30a-5p) together 
with the level of significance. The relative receiver operator curve (ROC, right) is shown with the Area Under 
the Curve (AUC). Each of the top 6 significant CIR-miRNAs is a good-to-excellent biomarker and CIR-miRNAs 
were mostly downregulated in Sepsis compared to SIRS in Exiqon miRNA qPCR arrays. (B) A model combines 
the top-6 significant CIR-miRNAs to maximize distinction between SIRS and sepsis. The CIR-miRNA score is 
directly related to the odds of having SIRS or sepsis given the measurements of the 6 top miRNAs (see Material 
and Methods for further details). Left dot plot shows the model interpolation of the experimental cohort: SIRS 
patients -that have high CIR-miRNA levels (in A)- tend to score > 0, whilst sepsis patients tend to score < 0. ROC 
(and AUC, right) shows that the 6 CIR-miRNAs combined outperformed single miRNAs.
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markers of these conditions. Combined together, these CIR-miRNAs were more discriminatory than traditional 
sepsis biomarkers such as PCT (Supplementary Fig. 3) and CRP29. Notably, we found that CIR-miRNA levels 
correlate inversely with pro-inflammatory mediators.
Previous studies exploring the effect of sepsis and SIRS on circulating miRNAs have typically studied indi-
vidual miRNAs shortlisted from mouse models or human cells21, stimulated with lipopolysaccharide (LPS)22–26, 
made comparisons with healthy controls14,18,19 (rather than SIRS patients15,16,19,21) or comparisons within sepsis 
patients for prognostic implications17,18,20. Often, these studies had small patient cohorts (analyzed as individuals) 
and did not account for the nature of the underlying infection during sepsis and for severity of illness14–21, both 
affecting the inflammatory response40. Only in two previous studies14,17, have circulating miRNAs been sought 
primarily with a genome-wide approach (with miRNA microarrays14 being less sensitive than NGS). Many previ-
ous studies14–21 have suffered from lack of rigorous normalization41 and bias coming from hemolysis (promoting 
the release miRNAs from RBCs31,32).
Our study overcomes such limitations providing a definitive evaluation of CIR-miRNAs in human sepsis 
and SIRS. We propose a novel approach to the normalization of blood miRNAs. First, we excluded the bias of 
RBC-derived miRNAs form our analysis by balancing free Hb levels across the experimental groups and -unlike 
in any previous study14,17,41- we normalized CIR-miRNAs against endogenous normalizing plasma miRNAs42 
consistently expressed across all recruited individuals. The best normalizer for our dataset was a combination 
of miR-320a and miR-486-5p (while miR-92b-3p was excluded because its levels fell below the detection limit 
of qPCR in many individuals). Interestingly, miR-320a and miR-486-5p were included in the 5 best miRNAs for 
least concentration variations in plasma and/or serum in a recent detailed study of blood miRNAs (with n = 12 
individuals) by an independent group9, suggesting that these miRNAs may be useful endogenous normalizers. 
Additionally, miR-486-5p is one of the most abundant miRNAs in RBC9 and its blood amounts may derive mostly 
by RBC31. Hence, it is not surprising that, after balancing haemolysis across the samples prior to miRNA analysis, 
Figure 5. Correlation of the model scores with pathology scores and plasma levels of immune mediators 
relevant in sepsis and SIRS. The model scores that combine the top-6 CIR-miRNA measurements in Severe 
SIRS and Severe Sepsis patients were plotted against (A) the pathology score (SOFA, sequential organ failure 
assessment); (B) current biomarkers of sepsis and inflammation, CRP (C-reactive protein) and PSP (pancreatic 
soluble protein); and (C) inflammatory cytokines, IL-6, IL-8, and IL-1. Correlation trends are shown with 
the linear regression model including Spearman rho and the significances of the correlations. Negative scores 
-typical of sepsis patients with lower plasma CIR-miRNAs (as in Fig. 4)- correspond to individuals with 
increased levels of inflammatory mediators. Positive scores -more often seen in SIRS patients and reflective 
of high plasma CIR-miRNAs- are found in individuals with low levels of inflammatory cytokines. Thus, 
CIR-miRNA levels negatively correlate with pro-inflammatory cytokines critical in systemic inflammatory 
conditions.
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we found relative stability of miR-486-5p in the individuals from our cohort. This supports that a two-stage nor-
malization (Hb and endogenous miRNA) approach may enable the use of RBC-derived miRNAs as endogenous 
normalizers in future studies.
Interestingly none of the previously proposed “biomarkers of sepsis” was included in our best CIR-miRNAs 
that discriminate sepsis from SIRS, except for miR-23a (also found in14). We however confirmed modulation of 
miR-146a, miR-122, miR-223, and the Let-7 family- which collectively showed a tendency to decrease in sepsis 
compared to SIRS (Table 2). Hence, in contrast to previous reports we did not find increased levels of miR-223 
and miR-146a14,17,18,43,44 associated with sepsis over SIRS. These differences likely result from the fact that previous 
studies compared sepsis patients directly to healthy individuals (rather than SIRS patients). In agreement, relative 
to control patients (no-SIRS), we also found that CIR-miRNAs are generally up-regulated in sepsis, thus recon-
ciling our study with previous literature. Further our study is compatible with a previous report16 in which both 
miR-223 and miR-146a are reduced in sepsis compared to SIRS. Interestingly, 6/7 miRNAs investigated in the 
same study also showed a tendency to decrease in sepsis compared to SIRS. Other miRNAs previously proposed 
as “biomarkers of sepsis”, including miR-15a and miR-1619, miR-15014,21 (in agreement with15), and miR-4772-
5p-iso21 were not confirmed in our independent cohort.
As we used the CRP to define our experimental groups, we cannot provide a direct comparison of the bio-
marker performance of CIR-miRNAs and CRP in this study. Nevertheless, within our own data the combination 
of the top 6 CIR-miRNAs outperformed the most discriminatory existing marker, PCT (Supplementary Fig. 3)29 
and exceeds previously published performance of CRP29. The time of sample collection, sex, survival outcome, age 
and SOFA scores did not significantly affect the measurements of shortlisted CIR-miRNAs (Supplementary Fig. 4). 
Importantly, the predictive value of the top 6 CIR-miRNAs (either used alone or in combination) was generally 
well-preserved after controlling for a number of confounding variables in our cohort (Supplementary Fig. 4). 
However, our study observations remain limited to a single cohort of patients and as such constitute a “hypothesis 
generating” study. A larger prospective study will be needed to consolidate the proposed CIR-miRNAs as disease 
biomarkers in a different population. For instance, it should be noted that the small number of recruited patients 
with non-severe sepsis (n = 8) precluded the statistical analysis of the non-severe groups and future research will 
be needed to assess how CIR-miRNA levels are affected by disease severity. After matching for age, severity of the 
disease, time of sample collection, sex and free Hb, our study populations showed an intrinsic heterogeneity in 
the surgical to medical patient ratio (as 100% abdominal sepsis patients underwent surgery, decreased to average 
65% in the control groups). Future studies should assess the impact of the focus of infection and surgery on levels 
of CIR-miRNAs.
It is presently unclear whether any of the top 6 CIR-miRNAs play a role in sepsis and SIRS. However, 
miR-191 and miR-26a have been recently associated with inflammatory and autoimmune conditions in humans 
and mice45–47. Particularly, miR-26a was reported to limit inflammatory responses possibly by promoting regu-
latory T cell responses46 or through NF-kB inhibition in chondrocytes47. Also miR-23a has been implicated in 
inflammation via multiple pathways and it may: attenuate the cytotoxic activity in CD8 T cells48; limit excessive 
T cell immunopathology by regulating reactive oxygen species49; and/or regulate pro-inflammatory cytokine 
expression following TLR-signal in macrophages, via the NF-kB pathway50. Kinases and transcription factors 
important in immune-cell differentiation and regulation such as Blimp-151, p53/MDM252 and PTEN53 may be tar-
gets of miR-30a, miR-30d, miR-192 and miR26a, all CIR-miRNAs downregulated in sepsis, in our study. Further 
research in our laboratory is underway to evaluate whether and how these genes are relevant in sepsis.
Figure 6. Proposed model for CIR-miRNA and inflammatory mediator plasma levels. The triangular shapes 
represent plasma levels of CIR-miRNA (circulating miRNA, top) and pro-inflammatory mediators (bottom). 
Based on our results, in Sepsis we found low levels of CIR-miRNAs correlating with increasing levels of pro-
inflammatory mediators (dark red). In contrast, in SIRS patients CIR-miRNAs are more abundant than what 
is found for sepsis patients correlating with lower levels of pro-inflammatory markers (blue). We speculate that 
immunologically relevant CIR-miRNAs may exist that act as regulators of inflammatory processes especially 
during systemic inflammatory diseases. This hypothesis is consistent with recent data showing that regulatory 
cells secrete exosomes which exert miRNA-mediated immune-suppression.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:28006 | DOI: 10.1038/srep28006
We provide evidence that will support future studies defining the origin of CIR-miRNAs, whether they traffic 
in blood inside exosomes (vesicles) or in complexes with Argonaute8,54, their targets and function. The magni-
tude of the changes we have observed in inflammation and the correlations with inflammatory cytokines suggest 
that CIR-miRNAs originate in cells of the immune system55,56. We find that levels of CIR-miRNAs inversely 
correlate with levels of inflammatory cytokines that are typically elevated in sepsis such as IL-1β , IL-6, and IL-8, 
and CRP3,57. This opens up the possibility that CIR-miRNAs may be part of the anti-inflammatory response4 
suppressing immune cell activation in severe sepsis and inflammation (Fig. 6). This hypothesis is compatible with 
the recent discovery that (murine) regulatory T cells suppress inflammatory responses by secreting a number of 
miRNAs analogous to the human CIR-miRNAs found in this study56. How exactly the CIR-miRNAs fit into the 
inflammatory cascade in sepsis and SIRS remains to be determined in future studies. For example, miRNAs may 
be detected by Toll-like receptors as danger signals58,59 and transferred to antigen presenting cells60, NK59 and T56 
cells to drive cell-differentiation. Also, individual cellular miRNAs were shown to regulate inflammatory signaling 
cascades leading to immune cell activation or suppression (reviewed in61–63 and50).
In summary, among critically ill patients, elevation of CIR-miRNAs is a hallmark of systemic inflamma-
tion. Quantitative and qualitative differences in CIR-miRNA levels exist in sepsis and non-infective SIRS. Our 
study provides proof-of-principle that sepsis and non-infective SIRS are associated with distinct changes in 
CIR-miRNAs which may be exploited for novel therapeutic and diagnostic approaches, whilst future investi-
gations of the role of CIR-miRNAs in the immunopathogenesis of sepsis and non-infective SIRS are warranted.
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